OSE Immunotherapeutics Email Format

Biotechnology ResearchPays de la Loire, France51-200 Employees

OSE Immunotherapeutics is a French biotechnology research company based in Nantes that focuses on developing first-in-class assets in immuno-oncology and immuno-inflammation, with a workforce of 51-200 employees. Its product portfolio includes Tedopi, a therapeutic cancer vaccine in Phase 3 for second-line NSCLC in HLA-A2+ patients with secondary resistance, as well as Lusvertikimab (an IL-7R antagonist) with a positive Phase 2 in ulcerative colitis and preclinical work in ALL, and OSE-279 (anti-PD1) with early Phase 1/2 results. The pipeline also features FR-104/VEL-101 (anti-CD28 mAb) developed in partnership with Veloxis for transplantation, an anti-SIRPα mAb developed with Boehringer Ingelheim, and ABBV-230 (ChemR23 agonist mAb) developed with AbbVie. OSE Immunotherapeutics operates four proprietary drug discovery platforms: Pro-resolutive mAb platform, Myeloid Checkpoint platform, BiCKI, and an mRNA Therapeutic platform. Strategic collaborations include an exclusive Veloxis licensing and co-development agreement established in 2021, along with partnerships with Boehringer Ingelheim and AbbVie; in 2026 the company announced leadership changes with Marc Le Bozec appointed as CEO and Thomas Gidoin named Deputy CEO, and scheduled governance events such as an AGM in Paris.

Sign up for free to view info

Company overview Employee directory